CN114763319B - 一种联产丙戊酰胺和丙戊酸钠的方法 - Google Patents
一种联产丙戊酰胺和丙戊酸钠的方法 Download PDFInfo
- Publication number
- CN114763319B CN114763319B CN202210529577.6A CN202210529577A CN114763319B CN 114763319 B CN114763319 B CN 114763319B CN 202210529577 A CN202210529577 A CN 202210529577A CN 114763319 B CN114763319 B CN 114763319B
- Authority
- CN
- China
- Prior art keywords
- valproate
- formula
- acid
- cyano
- cyanoacetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title claims abstract description 65
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 title claims abstract description 65
- 229940084026 sodium valproate Drugs 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 47
- 229940102566 valproate Drugs 0.000 claims abstract description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 36
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 238000006136 alcoholysis reaction Methods 0.000 claims abstract description 20
- 239000002253 acid Substances 0.000 claims abstract description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 14
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 claims abstract description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 9
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 8
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 7
- 230000003197 catalytic effect Effects 0.000 claims abstract description 6
- 239000003513 alkali Substances 0.000 claims abstract description 5
- 230000009471 action Effects 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- 229960000604 valproic acid Drugs 0.000 claims description 31
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 23
- 239000003054 catalyst Substances 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical group COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 10
- 230000007062 hydrolysis Effects 0.000 claims description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 8
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical group [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 5
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 5
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- BESQLCCRQYTQQI-UHFFFAOYSA-N propan-2-yl 2-cyanoacetate Chemical compound CC(C)OC(=O)CC#N BESQLCCRQYTQQI-UHFFFAOYSA-N 0.000 claims description 4
- NLFIMXLLXGTDME-UHFFFAOYSA-N propyl 2-cyanoacetate Chemical compound CCCOC(=O)CC#N NLFIMXLLXGTDME-UHFFFAOYSA-N 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 4
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 3
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 claims description 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 claims description 2
- 239000004412 Bulk moulding compound Substances 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 claims description 2
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 claims description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 claims description 2
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 claims description 2
- DJACTCNGCHPGOI-UHFFFAOYSA-N butyl 2-cyanoacetate Chemical compound CCCCOC(=O)CC#N DJACTCNGCHPGOI-UHFFFAOYSA-N 0.000 claims description 2
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229940019778 diethylene glycol diethyl ether Drugs 0.000 claims description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 2
- VVNBOKHXEBSBQJ-UHFFFAOYSA-M dodecyl(triethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](CC)(CC)CC VVNBOKHXEBSBQJ-UHFFFAOYSA-M 0.000 claims description 2
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 claims description 2
- FZPXKEPZZOEPGX-UHFFFAOYSA-N n,n-dibutylaniline Chemical compound CCCCN(CCCC)C1=CC=CC=C1 FZPXKEPZZOEPGX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- BFNYNEMRWHFIMR-UHFFFAOYSA-N tert-butyl 2-cyanoacetate Chemical compound CC(C)(C)OC(=O)CC#N BFNYNEMRWHFIMR-UHFFFAOYSA-N 0.000 claims description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 claims description 2
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 claims description 2
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 claims description 2
- UQFSVBXCNGCBBW-UHFFFAOYSA-M tetraethylammonium iodide Chemical compound [I-].CC[N+](CC)(CC)CC UQFSVBXCNGCBBW-UHFFFAOYSA-M 0.000 claims description 2
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 claims description 2
- RXMRGBVLCSYIBO-UHFFFAOYSA-M tetramethylazanium;iodide Chemical compound [I-].C[N+](C)(C)C RXMRGBVLCSYIBO-UHFFFAOYSA-M 0.000 claims description 2
- BGQMOFGZRJUORO-UHFFFAOYSA-M tetrapropylammonium bromide Chemical compound [Br-].CCC[N+](CCC)(CCC)CCC BGQMOFGZRJUORO-UHFFFAOYSA-M 0.000 claims description 2
- HNJXPTMEWIVQQM-UHFFFAOYSA-M triethyl(hexadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](CC)(CC)CC HNJXPTMEWIVQQM-UHFFFAOYSA-M 0.000 claims description 2
- NAWZSHBMUXXTGV-UHFFFAOYSA-M triethyl(hexyl)azanium;bromide Chemical compound [Br-].CCCCCC[N+](CC)(CC)CC NAWZSHBMUXXTGV-UHFFFAOYSA-M 0.000 claims description 2
- FASLCARXKMYXDH-UHFFFAOYSA-M triethyl(octyl)azanium;bromide Chemical compound [Br-].CCCCCCCC[N+](CC)(CC)CC FASLCARXKMYXDH-UHFFFAOYSA-M 0.000 claims description 2
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 claims description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical group [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims 1
- URWCEDLDYLLXCC-UHFFFAOYSA-M decyl(triethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](CC)(CC)CC URWCEDLDYLLXCC-UHFFFAOYSA-M 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 abstract description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000007787 solid Substances 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000001035 drying Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 12
- 238000002390 rotary evaporation Methods 0.000 description 12
- 229910017053 inorganic salt Inorganic materials 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000000967 suction filtration Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 6
- 229960001930 valpromide Drugs 0.000 description 6
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 238000004821 distillation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 3
- UZRGQIZTJOPZGE-UHFFFAOYSA-N 2-cyano-2-propylpentanoic acid Chemical compound CCCC(C(O)=O)(C#N)CCC UZRGQIZTJOPZGE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 3
- WPRYUWYMOZQHIY-UHFFFAOYSA-N methyl 2-propylpentanoate Chemical compound CCCC(CCC)C(=O)OC WPRYUWYMOZQHIY-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- -1 dipropyl acetoacetate Chemical compound 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003408 phase transfer catalysis Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- FWDBZJBJTDRIIY-UHFFFAOYSA-N CC(C)(C)[K] Chemical compound CC(C)(C)[K] FWDBZJBJTDRIIY-UHFFFAOYSA-N 0.000 description 1
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RCUIWQWWDLZNMS-UHFFFAOYSA-N benzyl 2-cyanoacetate Chemical compound N#CCC(=O)OCC1=CC=CC=C1 RCUIWQWWDLZNMS-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003442 catalytic alkylation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- CREVBWLEPKAZBH-UHFFFAOYSA-M hydron;tetraethylazanium;sulfate Chemical compound OS([O-])(=O)=O.CC[N+](CC)(CC)CC CREVBWLEPKAZBH-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- QSUJAUYJBJRLKV-UHFFFAOYSA-M tetraethylazanium;fluoride Chemical compound [F-].CC[N+](CC)(CC)CC QSUJAUYJBJRLKV-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0201—Oxygen-containing compounds
- B01J31/0211—Oxygen-containing compounds with a metal-oxygen link
- B01J31/0212—Alkoxylates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0231—Halogen-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/18—Preparation of carboxylic acid esters by conversion of a group containing nitrogen into an ester group
- C07C67/22—Preparation of carboxylic acid esters by conversion of a group containing nitrogen into an ester group from nitriles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Materials Engineering (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及化学结构式Ⅰ所示的丙戊酰胺和式Ⅱ所示的丙戊酸钠的制备方法;其特征在于氰基乙酸酯与1‑氯丙烷,在碱作用下,复合催化二丙基化制得式Ⅲ所示的2‑氰基‑2‑丙戊酸酯;2‑氰基‑2‑丙戊酸酯经水解和脱酸得到式Ⅴ所示的丙戊腈;丙戊腈在酸催化下醇解,制得式Ⅰ所示的丙戊酰胺和式Ⅵ所示的丙戊酸酯;丙戊酸酯在氢氧化钠溶液中水解得到式Ⅱ所示的丙戊酸钠;其制备反应如下:
Description
技术领域
本发明涉及一种2-氰基-2-丙戊酸酯的相转移复合催化制备方法及其在联产丙戊酸(钠)和丙戊酰胺中的应用。
背景技术
丙戊酸钠和丙戊酰胺都是抗癫痫药,其治疗范围是不一样。丙戊酸钠为原发性大发作和失神小发作的首选药,对部分性发作(简单部分性和复杂部分性及部分性发作继发大发作)疗效不佳;丙戊酸钠对婴儿良性肌阵挛癫痫、婴儿痉挛有一定疗效,对肌阵挛性失神发作需加用乙琥胺或其他抗癫痫药才有效。丙戊酰胺是一种新的抗癫痫药,药理实验表明期抗癫痫作用是丙戊酸钠的2倍。
周启群等[丙戊酸钠合成工艺改进.中国医药工业杂志.1993,24(8):347-348]选择乙酰乙酸甲酯经季铵盐固液相转移催化烷基化、脱酰基、水解、成盐制得丙戊酸钠:
王学勤等[丙戊酸钠合成新工艺.中国医药工业杂志,1999,30(9):389-390]选择乙酰乙酸甲酯和碳酸钾,在TBAB催化下,与1-溴丙烷缩合得二丙基乙酰乙酸酯,收率63.1%。2019年林凡友[一种丙戊酸钠的合成工艺,CN110563572A,2019-12-13]也采用TBAB相转移催化制备一种丙戊酸钠。
李辛缘等[固液相转移催化反应合成丙戊酸类抗癫痫药物.医药工业,1984,5:4-6]和美国专利[US4127604]选择氰基乙酸甲酯、1-溴丙烷和固体碳酸钾,在季铵盐催化下二丙烷基化,再经水解、脱羧和再水解制得丙戊酰胺,后者与亚硝酸反应制得丙戊酸,最后成盐得到丙戊酸钠。亚硝酸分解产生的一氧化氮和二氧化氮对环境有污染,对设备有腐蚀。
2-氰基-2-丙基戊酸脱羧和水解制得的丙戊酰胺,后者制备丙戊酸的过程如下:
上海青平药业有限公司[一种丙戊酸制备新方法,CN 2021103366414,2021.8.3;一种丙戊酸钠的制备方法,CN2021103339474,2021.8.3;一种制备丙戊酸的方法,CN2021103366274,2021.7.27]公开了一种制备丙戊酸和丙戊酸钠的方法:以丙戊腈或2-氰基-2-丙基戊酸为起始物料通过一锅法制备丙戊酸。以丙戊腈或2-氰基-2-丙基戊酸为原料,使用硫酸水溶液为催化剂,在120~160℃反应20h~40h,制得丙戊酸,收率70%~80%;该方法的水解温度高,反应时间长。其合成路线如下:
该工艺采用硫酸高温脱羧和水解,可能发生副反应,且危险系数大。
刘卫国[一种丙戊酸钠的制备方法,CN201811564128.5,2020-06-3]选择戊酸乙酯为原料制备丙戊酸钠,工艺路线如下:
该发明的制备丙戊酸的工艺中需要非常强的碱——吡咯锂盐和低温。
发明内容
本发明的目的一方面是提供联产化学结构式Ⅰ所示的丙戊酰胺和式Ⅱ所示的丙戊酸钠的方法,其特征在于氰基乙酸酯与1-氯丙烷,在碱作用下,复合催化二丙基化制得式Ⅲ所示的2-氰基-2-丙戊酸酯;2-氰基-2-丙戊酸酯经水解和脱酸得到式Ⅴ所示的丙戊腈;丙戊腈在酸催化下醇解,制得式Ⅰ所示的丙戊酰胺和式Ⅵ所示的丙戊酸酯;丙戊酸酯在氢氧化钠溶液中水解得到式Ⅱ所示的丙戊酸钠;其制备反应如下:
其中,式Ⅲ所示的2-氰基-2-丙戊酸酯的制备方法,其特征在于氰基乙酸酯与1-氯丙烷,在碱作用下,复合催化二丙基化制得式Ⅲ所示的2-氰基-2-丙戊酸酯;其制备反应如下:
R=甲基或乙基;
催化剂由催化剂A和催化剂B组成;
催化剂A选择:R3N、PhNR2、R4NX或R3R1NX;其中R=C1~C4直链烷基、C5~C8直链烷基;R1=PhCH2、C1~C5直链烷基、C6~C18直链烷基;其中X=F、Cl、Br、I或HSO4;
催化剂B选择MX;其中M=Na、Li、Cs、K,X=F、Cl、Br或I。
R4NX选自:四丁基氯化铵、四丁基溴化铵、四丁基碘化铵、四丁基硫酸氢铵、四乙基氟化铵、四乙基氯化铵、四乙基溴化铵、四乙基碘化铵、四乙基硫酸氢铵、四甲基氯化铵、四甲基溴化铵、四甲基碘化铵或四丙基溴化铵。
R3R1NX选自:十六烷基三甲基溴化铵、十八烷基三甲基溴化铵、三乙基苄基氯化铵、三甲基苄基氯化铵、三乙基苄基溴化铵、十六烷基三乙基溴化铵、十二烷基三乙基溴化铵、十烷基三乙基溴化铵、辛基三乙基溴化铵、己基三乙基溴化铵或三辛基甲基氯化铵。
R3N选自:三甲胺、三乙胺、三丙胺、三丁胺;PhNR2选自:N,N-二甲苯胺、N,N-二乙苯胺、N,N-二丙苯胺或N,N-二丁苯胺。
MX选自:NaBr、KBr、NaI或KI。
溶剂选择:THF、DMF、DMC、DMSO、乙腈、丙腈、丁腈、1,4-二氧六环、乙二醇二甲醚、乙二醇二乙醚、二乙二醇二甲醚、二乙二醇二乙醚、乙酸乙酯或乙酸丁酯中的一种或二种。
碱选自:固体MOH或固体M2CO3,其中M=Na、Li、Cs或K;固体MOH选择颗粒或粉状MOH;固体M2CO3选择颗粒M2CO3或粉状M2CO3;其中M=Na、Li、Cs或K。
粉状M2CO3选择:100目M2CO3、150目M2CO3、200目M2CO3、250目M2CO3、300目M2CO3或350目M2CO3,其中M=Na、Li、Cs或K。
反应温度选择:60℃~120℃;反应时间选择:1.0h~12h;
催化用量选择:氰基乙酸酯∶催化剂A∶催化剂B=1∶0.01~0.10∶0.005~0.05摩尔比;氰基乙酸酯选自:氰基乙酸甲酯、氰基乙酸乙酯、氰基乙酸正丙酯、氰基乙酸异丙酯、氰基乙酸正丁酯、氰基乙酸叔丁酯或氰基乙酸苄酯。
其中,式Ⅴ所示的丙戊腈的醇解方法,其特征在于丙戊腈在酸催化下与醇反应,制得丙戊酰胺(固体)和式Ⅵ所示的丙戊酸酯(液体);其制备反应如下:
其中,R=甲基或乙基;醇解反应中,酸(酸性物质)选自:HCl(g)、AlCl3、硫酸、二氯亚砜、三氟甲磺酸、甲磺酸、苯磺酸、对甲苯磺酸或三氟甲磺酸三甲基硅酯。
醇解反应中,酸的摩尔用量选自:丙戊腈∶酸=1∶1.2~4;
醇解反应中,酸的质量浓度选自:30%~70%;
醇ROH摩尔用量选自:丙戊腈∶ROH=1∶3~8;
醇解反应中,醇解温度选自:25℃~100℃
醇解反应中,醇解时间选自:4h~24h;
本发明的第二方面是提供联产式Ⅰ所示的丙戊酰胺和式Ⅱ所示的丙戊酸钠的方法,其特征在于式Ⅴ所示的丙戊腈经醇解和水解制得丙戊酰胺和丙戊酸钠;其制备反应如下:
其中,R=甲基或乙基。
酸选自:HCl(g)、AlCl3、硫酸、二氯亚砜、三氟甲磺酸、甲磺酸、苯磺酸、对甲苯磺酸或三氟甲磺酸三甲基硅酯;产物的摩尔比:n丙戊酰胺∶n丙戊酸钠=1∶1.5~8.0。
本发明的第三方面是提供一种联产式Ⅰ所示的丙戊酰胺和式Ⅶ所示的丙戊酸的方法,其特征在于式Ⅴ所示的丙戊腈经醇解和水解制得丙戊酰胺和丙戊酸;其制备反应如下:
其中,R=甲基或乙基。
酸选自:HCl(g)、AlCl3、硫酸、二氯亚砜、三氟甲磺酸、甲磺酸、苯磺酸、对甲苯磺酸或三氟甲磺酸三甲基硅酯;产物的摩尔比:n丙戊酰胺∶n丙戊酸=1∶1.5~8.0。
本发明与现有技术相比具有以下优点:
1.本发明中,采用氰基乙酸酯和1-氯丙烷的复合催化二丙基化方法:1-氯丙烷供应充足,来源丰富,且价廉;该关键性二丙基化反应完全,为最终产品高质量提供保障!一条生产路线可联产高质量的二种抗癫痫药——丙戊酸钠和丙戊酰胺。
2.本发明生产工艺路线中不使用强碱甲醇钠、乙醇钠或叔丁钾,也不使用价格较贵的1-溴丙烷;创造性地避免了下列副产物的产生:
3.本发明生产工艺中的中间体和产品纯度高,分离简单;依据市场需求,可以通过控制醇解的反应条件调控联产原料药丙戊酸(钠)和丙戊酰胺的产量比例;生产设备投资少,设备利用率高,生产成本低,质量好。具有很好的社会效益与经济效益。
具体实施方式
下面结合实施例对本发明进行进一步的详细说明。
实施例1
2-氰基-2-丙戊酸甲酯的制备
29.73g(0.30mol)氰基乙酸甲酯、12.0mmol四丁基溴化铵、3.0mmolKI、91.21g(0.66mol)K2CO3、120ml DMF和58.91g(0.75mol)1-氯丙烷,85℃搅拌反应3.0h(TLC监测反应完成),反应毕,稍冷后过滤无机盐;减压回收110ml DMF;石油醚洗涤无机盐;有机相用水洗涤至水相无色,无水硫酸钠干燥有机相,抽滤回收硫酸钠,旋蒸有机相,干燥得53.06g 2-氰基-2-丙戊酸甲酯,收率96.50%(以氰基乙酸甲酯计);1H NMR(400MHz,DMSO-d6)δ:3.76(s,3H,OCH3),1.85–1.75(m,4H,CH2×2),1.52–1.38(m,2H,CH2),1.30–1.17(m,2H,CH2),0.91(t,J=7.2Hz,6H,CH3×2)。
实施例2
2-氰基-2-丙戊酸的制备
29.73g(0.30mol)氰基乙酸甲酯、12.0mmol四丁基氯化铵、3.0mmolKI、91.21g(0.66mol)K2CO3、120ml乙二醇二甲醚和58.91g(0.75mol)1-氯丙烷,85℃搅拌反应2.5h(TLC监测反应完成),反应毕,稍冷后过滤无机盐;减压回收110ml乙二醇二甲醚;乙酸乙酯洗涤无机盐;无机盐为KCl和KHCO3,回收;有机相用水洗涤至水相无色,蒸溜回收乙酸乙酯,在残留的淡黄色透明液体(2-氰基-2-丙戊酸甲酯)中,加150ml 15%KOH,升温水解3h,加浓盐酸中和,析出固体,干燥得白色固体48.69g 2-氰基-2-丙戊酸,收率95.90%(以氰基乙酸甲酯计),熔点49~50℃。1HNMR(400MHz,DMSO-d6)δ:13.76(s,1H,CO2H),1.84–1.67(m,4H,CH2×2),1.54–1.41(m,2H,CH2),1.36–1.21(m,2H,CH2),0.92(t,J=7.2Hz,6H,CH3×2)。
实施例3
2-氰基-2-丙戊酸的制备
29.73g(0.30mol)氰基乙酸甲酯、3.33g(9.0mmol)TBAB、3.0mmolKI、91.21g(0.66mol)K2CO3、120ml DMF和58.91g(0.75mol)1-氯丙烷,85℃搅拌反应3.3h(TLC监测反应完成),反应毕,冷却,过滤无机盐;减压回收110ml DMF;石油醚(100ml×3)洗无机盐,无机盐为KCl和KHCO3;50ml×3水洗有机相,蒸馏回收石油醚,得到淡黄色透明液体(2-氰基-2-丙戊酸酯)。在2-氰基-2-丙戊酸酯淡黄色透明液体中,加150ml 15%KOH,65℃水解3h,冰浴下加入浓盐酸中和,析出白色沉淀,过滤,干燥得白色固体49.10g 2-氰基-2-丙戊酸,收率96.72%(以氰基乙酸甲酯计),熔点49~50℃。1HNMR(400MHz,DMSO-d6)δ:13.76(s,1H,CO2H),1.84–1.67(m,4H,CH2×2),1.54–1.41(m,2H,CH2),1.36–1.21(m,2H,CH2),0.92(t,J=7.2Hz,6H,CH3×2)。
实施例4
2-氰基-2-丙戊酸乙酯的制备
22.6g(0.20mol)氰基乙酸乙酯、10mmolTBAC、5mmolKI、60.8g(0.44mol)K2CO3(200目)、80ml DMF和39.3g(50mmol)1-氯丙烷,80℃搅拌反应6h,过滤回收无机盐;减压回收72ml DMF,加100ml石油醚,有机相用水洗涤至水相无色,无水硫酸钠干燥,抽滤,旋蒸,干燥得37.4g 2-氰基-2-丙戊酸乙酯,收率94.9%(以氰基乙酸乙酯计)。1HNMR(400MHz,DMSO-d6)δ:4.22(q,J=7.2Hz,2H,OCH2),1.84–1.75(m,4H,CH2×2),1.52–1.39(m,2H,CH2),1.31–1.18(m,5H,CH2+CH3),0.91(t,J=7.2Hz,6H,CH3×2)。
实施例5
2-氰基-2-丙戊酸的制备
22.6g(0.20mol)氰基乙酸乙酯、1mmol TBAC,60.8g(0.44mmol)K2CO3(100目),20mlDMF、60ml乙酸丁酯和5mmol溴化钾,39.3g(0.5mmol)1-氯丙烷,80℃搅拌反应6h,过滤回收无机盐;减压回收52ml乙酸丁酯和17ml DMF,加100ml石油醚,,有机相用水洗涤至水相无色,旋蒸回收石油醚,在残留的淡黄色透明液体(2-氰基-2-丙戊酸乙酯)中,加15ml 15%KOH,升温水解3h,加浓盐酸中和,析出固体,干燥得白色固体3.13g 2-氰基-2-丙戊酸,收率92.60%(以氰基乙酸乙酯计),熔点49~50℃。1HNMR(400MHz,DMSO-d6)δ:13.76(s,1H,CO2H),1.84–1.67(m,4H,CH2×2),1.54–1.41(m,2H,CH2),1.36–1.21(m,2H,CH2),0.92(t,J=7.2Hz,6H,CH3×2)。
实施例6
2-氰基-2-丙戊酸甲酯的制备
29.73g(0.30mol)氰基乙酸甲酯、15.0mmol三丁胺,91.21g(0.66mol)K2CO3(300目)、120ml回收的DMF和5.0mmol碘化钾和58.91g(0.75mol)1-氯丙烷,85℃搅拌反应4.0h(TLC监测反应完成),反应毕,过滤回收无机盐;石油醚洗涤,有机相用水洗涤至水相无色,无水硫酸钠干燥,抽滤,旋蒸,干燥得53.46g 2-氰基-2-丙戊酸甲酯,收率94.36%。1H NMR(400MHz,DMSO-d6)δ:3.76(s,3H,OCH3),1.85–1.75(m,4H,CH2×2),1.52–1.38(m,2H,CH2),1.30–1.17(m,2H,CH2),0.91(t,J=7.2Hz,6H,CH3×2)。
实施例7
2-氰基-2-丙戊酸甲酯的制备
29.73g(0.30mol)氰基乙酸甲酯、9.0mmol回收的四丁基溴化铵、91.21g(0.66mol)K2CO3(300目)、120ml回收的DMF、2.0mmol碘化钾和58.91g(0.75mol)1-氯丙烷,85℃搅拌反应3.0h(TLC监测反应完成),过滤回收无机盐;石油醚洗涤,有机相用水洗涤至水相无色,无水硫酸钠干燥,抽滤,旋蒸,干燥得53.46g 2-氰基-2-丙戊酸甲酯,收率94.36%。1H NMR(400MHz,DMSO-d6)δ:3.76(s,3H,OCH3),1.85–1.75(m,4H,CH2×2),1.52–1.38(m,2H,CH2),1.30–1.17(m,2H,CH2),0.91(t,J=7.2Hz,6H,CH3×2)。
实施例8
2-氰基-2-丙戊酸正丙酯的制备
按实施例1的方法选择氰基乙酸正丙酯制备2-氰基-2-丙戊酸正丙酯。
实施例9
2-氰基-2-丙戊酸的制备
按实施例2的方法选择氰基乙酸正丙酯制备2-氰基-2-丙戊酸。
实施例10
2-氰基-2-丙戊酸异丙酯的制备
按实施例1的方法,选择氰基乙酸异丙酯制备2-氰基-2-丙戊酸异丙酯。
实施例11
2-氰基-2-丙戊酸的制备
按实施例2的方法,选择氰基乙酸异丙酯制备2-氰基-2-丙戊酸。
实施例12
丙戊腈的制备
84.6g 2-氰基-2-丙戊酸加入250ml圆底烧瓶中,升温至150~155℃,脱酸4.0h,分馏,收集165~175℃馏分,得55.7g无色油状物丙戊腈,收率89%。
实施例13
丙戊酰胺和丙戊酸钠的制备
(1)丙戊酰胺的制备
25.04g丙戊腈和25.63g甲醇,冰浴中,搅拌下滴加39.23g浓硫酸,85℃搅拌反应5h,加100ml水,搅拌,用氢氧化钠溶液调pH8,乙酸乙酯萃取,无水硫酸钠干燥,抽滤,旋蒸,烘干得固液混合物,加150ml石油醚,搅拌0.5h,静置过夜,抽滤,石油醚洗涤,滤液按第(2)步骤处理;白色固体经干燥得7.04g丙戊酰胺,收率24.6%(以丙戊腈计);熔点125.5~126℃。1HNMR(400MHz,DMSO-d6)δ:7.26(s,1H,CONH2),6.71(s,1H,CONH2),2.18–2.10(m,1H,CH),1.47–1.36(m,2H,CH2),1.28–1.17(m,6H,CH2+CH2×2),0.85(t,J=5.8Hz,6H,CH3×2)。
(2)丙戊酸钠的制备
第(1)中的滤液经旋蒸回收石油醚,在残液中加26g氢氧化钠20ml水和20ml甲醇,加热回流5h;冷却,滤液用50ml乙酸乙酯萃取(2×25ml),分离有机相,旋蒸回收乙酸乙酯,少量残留物为丙戊腈,回收;旋蒸浓缩水相,冷至室温,析出白色固体,过滤,于50℃下,真空烘干得丙戊酸钠。用乙酸乙酯加热溶解,滤液缓慢降至室温,析出大量白色固体,过滤,50℃下,真空烘干得17.57g丙戊酸钠,收率52.9%(以丙戊腈计)。
实施例14
丙戊酰胺和丙戊酸钠的制备
25.04g丙戊腈和25.63g甲醇,冰浴中,搅拌下滴加39.23g浓硫酸;反应液75℃搅拌10h,反应液冷却至室温,在搅拌下向反应液中加入100ml水,搅拌;滴加氢氧化钠溶液,搅拌中和至pH~8,150ml乙酸乙酯(3×50ml)萃取,旋蒸回收乙酸乙酯,得固液混合物,加入石油醚150ml,析出固体,抽滤,滤液按第(2)步骤处理;白色固体干燥得到5.4g丙戊酰胺,收率18.9%(以丙戊腈计),熔点125.5~126℃。1HNMR(400MHz,DMSO-d6)δ:7.26(s,1H,CONH2),6.71(s,1H,CONH2),2.18–2.10(m,1H,CH),1.47–1.36(m,2H,CH2),1.28–1.17(m,6H,CH2+CH2×2),0.85(t,J=5.8Hz,6H,CH3×2)。
第(1)中的滤液经旋蒸回收石油醚,在残液中加26g氢氧化钠20ml水和20ml甲醇,加热回流5h;冷却,滤液用50ml乙酸乙酯萃取(2×25ml),分离有机相,旋蒸回收乙酸乙酯,少量残留物为丙戊腈,回收;旋蒸浓缩水相,冷至室温,析出白色固体,过滤,于50℃下,真空烘干得丙戊酸钠。用乙酸乙酯加热溶解,滤液缓慢降至室温,析出大量白色固体,过滤,50℃下,真空烘干得17.96g丙戊酸钠,收率54.1%(以丙戊腈计)。
实施例15
丙戊酰胺和丙戊酸钠的制备
(1)丙戊酰胺的制备
25.04g丙戊腈和25.63g甲醇,冰浴中,搅拌下滴加39.23g浓硫酸,85℃搅拌反应6h,加100ml水,搅拌,用氢氧化钠溶液调pH8,乙酸乙酯萃取,无水硫酸钠干燥,抽滤,旋蒸,烘干得固液混合物,加150ml石油醚,搅拌0.5h,静置过夜,抽滤,石油醚洗涤,滤液按第(2)步骤处理;白色固体干燥得6.95g丙戊酰胺,收率24.3%(以丙戊腈计);熔点125.5~126℃。1HNMR(400MHz,DMSO-d6)δ:7.26(s,1H,CONH2),6.71(s,1H,CONH2),2.18–2.10(m,1H,CH),1.47–1.36(m,2H,CH2),1.28–1.17(m,6H,CH2+CH2×2),0.85(t,J=5.8Hz,6H,CH3×2)。
(2)丙戊酸钠的制备
第(1)中的滤液经旋蒸回收石油醚,在残液中加26g氢氧化钠20ml水和20ml甲醇,加热回流5h;冷却,旋蒸浓缩水相,冷至室温,析出白色固体,过滤,于50℃下,真空烘干得丙戊酸钠。用乙酸乙酯加热溶解,滤液缓慢降至室温,析出大量白色固体,过滤,50℃下,真空烘干得18.6g丙戊酸钠,收率56.2%(以丙戊腈计)。
实施例16
丙戊酰胺和丙戊酸钠的制备
CH3OH-HCl(g)替代甲醇和硫酸,按实施例15投料比和反应条件,经相同的后处理方法,分别得到丙戊酰胺和丙戊酸钠。
实施例17
丙戊酰胺和丙戊酸钠的制备
苯磺酸或对甲苯磺酸替代硫酸,按实施例15投料比和反应条件,经相同的后处理方法,分别得到丙戊酰胺和丙戊酸钠。
实施例18
丙戊酰胺和丙戊酸钠的制备
三氟甲磺酸或甲磺酸替代硫酸,按实施例15投料比和反应条件,经相同的后处理方法,分别得到丙戊酰胺和丙戊酸钠。
实施例19
丙戊酰胺和丙戊酸钠的制备
选择乙醇替代甲醇,按实施例15投料比和反应条件,经相同的后处理方法,分别得到丙戊酰胺和丙戊酸钠。
实施例20
丙戊酰胺和丙戊酸甲酯的制备
(1)丙戊酰胺的制备
125g丙戊腈和128g甲醇,冰浴中,搅拌下滴加196g浓硫酸,85℃搅拌反应5.5h,加500ml水,搅拌,用氢氧化钠溶液调pH8,乙酸乙酯萃取,无水硫酸钠干燥,抽滤,旋蒸,烘干得固液混合物,加700ml石油醚,搅拌0.5h,静置过夜,抽滤,石油醚洗涤,滤液按第(2)步骤处理;白色固体干燥得35g丙戊酰胺,收率24.5%(以丙戊腈计);熔点125.5~126℃。1HNMR(400MHz,DMSO-d6)δ:7.26(s,1H,CONH2),6.71(s,1H,CONH2),2.18–2.10(m,1H,CH),1.47–1.36(m,2H,CH2),1.28–1.17(m,6H,CH2+CH2×2),0.85(t,J=5.8Hz,6H,CH3×2)。
(2)丙戊酸甲酯的制备
第(1)中的滤液经旋蒸回收石油醚,减压精溜得到95g丙戊酸甲酯,收率60.1%(以丙戊腈计);1HNMR(400MHz,CDCl3)δ:3.67(s,3H,OCH3),2.43–2.32(m,1H,CH),1.65–1.53(m,2H,CH2),1.47–1.36(m,2H,CH2),1.33–1.23(m,4H,CH2×2),0.89(t,J=7.2Hz,6H,CH3×2)。
实施例21
丙戊酰胺和丙戊酸的制备
(1)丙戊酰胺的制备
125g丙戊腈和128g甲醇,冰浴中,搅拌下滴加196g浓硫酸,80℃搅拌反应8h,加500ml水,搅拌,用氢氧化钠溶液调pH8,乙酸乙酯萃取,无水硫酸钠干燥,抽滤,旋蒸,烘干得固液混合物,加700ml石油醚,搅拌0.5h,静置过夜,抽滤,石油醚洗涤,滤液按第(2)步骤处理;白色固体干燥得34g丙戊酰胺,收率23.7%(以丙戊腈计);熔点125.5~126℃。1HNMR(400MHz,DMSO-d6)δ:7.26(s,1H,CONH2),6.71(s,1H,CONH2),2.18–2.10(m,1H,CH),1.47–1.36(m,2H,CH2),1.28–1.17(m,6H,CH2+CH2×2),0.85(t,J=5.8Hz,6H,CH3×2)。
(2)丙戊酸的制备
第(1)中的滤液经旋蒸回收石油醚,在淡黄色液体中滴加氢氧化钾水溶液(KOH:120g,H2O:200g),升温85℃搅拌水解5h;冷却,分离水层;有机相加入350ml水,静置分层,分离油相,回收丙戊腈,水相加盐酸调pH至1,静置分层,油相干燥,减压精馏收集85~90℃/0.4kPa馏分84g丙戊酸,收率58.3%(以丙戊腈计);1HNMR(400MHz,DMSO-d6)δ:11.99(s,1H,COOH),2.24–2.18(m,1H,CH),1.53–1.44(m,2H,CH2),1.39–1.34(m,2H,CH2),1.32–1.22(m,4H,CH2×2),0.86(t,J=7.2Hz,6H,CH3×2)。
在本说明书中,本发明已参照其特定的实施例作了描述。但是,很显然仍可以作出各种修改和变换而不背离本发明的精神和范围。因此,说明书应被认为是说明性的而非限制性的。
Claims (9)
1.化学结构式Ⅰ所示的丙戊酰胺和式Ⅱ所示的丙戊酸钠的制备方法,其特征在于氰基乙酸酯与1-氯丙烷,在碱作用下,复合催化二丙基化制得式Ⅲ所示的2-氰基-2-丙戊酸酯;2-氰基-2-丙戊酸酯经水解和脱酸得到式Ⅴ所示的丙戊腈;丙戊腈在酸催化下醇解,制得式Ⅰ所示的丙戊酰胺和式Ⅵ所示的丙戊酸酯;丙戊酸酯在氢氧化钠溶液中水解得到式Ⅱ所示的丙戊酸钠;其制备反应如下:
其中,R2=甲基、乙基、C3~C5直链烷基或C3~C5支链烷基;R3=甲基或乙基;
式Ⅲ所示的2-氰基-2-丙戊酸酯的制备反应的催化剂由催化剂A和催化剂B组成;
催化剂A选自R3N、PhNR2、R4NX或R3R1NX;其中R=C1~C4直链烷基、C5~C8直链烷基;R1=PhCH2、C1~C5直链烷基、C6~C18直链烷基;其中X=Cl、Br或I;催化剂B选自NaBr、KBr,NaI或KI;
式Ⅲ所示的2-氰基-2-丙戊酸酯的制备反应的溶剂选自THF、DMF、DMC、DMSO、乙腈、丙腈、丁腈、1,4-二氧六环、乙二醇二甲醚、乙二醇二乙醚、二乙二醇二甲醚、二乙二醇二乙醚、乙酸乙酯或乙酸丁酯中的一种或二种;
式Ⅲ所示的2-氰基-2-丙戊酸酯的制备反应的碱选自颗粒M2CO3或粉状M2CO3;其中M=Na或K;
式Ⅴ所示的丙戊腈的醇解反应的酸选自氯化氢气体、三氯化铝、二氯亚砜、三氟甲磺酸、三氟甲磺酸三甲基硅酯、甲磺酸、苯磺酸、对甲苯磺酸或硫酸。
2.如权利要求1所述的制备方法,其特征在于其中R4NX选自四丁基氯化铵、四丁基溴化铵、四丁基碘化铵、四乙基氯化铵、四乙基溴化铵、四乙基碘化铵、四甲基氯化铵、四甲基溴化铵、四甲基碘化铵或四丙基溴化铵;
R3R1NX选自十六烷基三甲基溴化铵、十八烷基三甲基溴化铵、三乙基苄基氯化铵、三甲基苄基氯化铵、三乙基苄基溴化铵、十六烷基三乙基溴化铵、十二烷基三乙基溴化铵、十烷基三乙基溴化铵、辛基三乙基溴化铵、己基三乙基溴化铵或三辛基甲基氯化铵;
R3N选自三甲胺、三乙胺、三丙胺、三丁胺;PhNR2选自N,N-二甲苯胺、N,N-二乙苯胺、N,N-二丙苯胺或N,N-二丁苯胺。
3.如权利要求1所述的制备方法,其特征在于其中粉状M2CO3选自100目M2CO3、150目M2CO3、200目M2CO3、250目M2CO3、300目M2CO3或350目M2CO3,其中M=Na或K。
4.如权利要求1所述的制备方法,其中式Ⅲ所示的2-氰基-2-丙戊酸酯的制备方法,其特征在于反应温度选自60℃~120℃;反应时间选自1.0h~12h。
5.如权利要求1所述的制备方法,其中式Ⅲ所示的2-氰基-2-丙戊酸酯的制备方法,其特征在于氰基乙酸酯∶催化剂A∶催化剂B=1∶0.01~0.10∶0.005~0.05摩尔比;氰基乙酸酯选自氰基乙酸甲酯、氰基乙酸乙酯、氰基乙酸正丙酯、氰基乙酸异丙酯、氰基乙酸正丁酯或氰基乙酸叔丁酯。
6.如权利要求1所述的制备方法,其中式Ⅴ所示的丙戊腈的醇解反应,其特征在于丙戊腈∶酸=1∶1.2~4摩尔比;酸的质量浓度选自30%~70%;丙戊腈∶R3OH=1∶3~8摩尔比。
7.如权利要求1所述的制备方法,其中式Ⅴ所示的丙戊腈的醇解反应,其特征在于反应温度选自25℃~100℃;醇解反应时间选自4h~24h。
8.如权利要求1所述的制备方法,其中式Ⅴ所示的丙戊腈的醇解反应制得式Ⅰ所示的丙戊酰胺和式Ⅵ所示的丙戊酸酯;丙戊酸酯在氢氧化钠溶液中水解得到式Ⅱ所示的丙戊酸钠;其特征在于Ⅰ和Ⅱ的摩尔比选自n丙戊酰胺∶n丙戊酸钠=1∶1.5~8.0。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210529577.6A CN114763319B (zh) | 2022-05-16 | 2022-05-16 | 一种联产丙戊酰胺和丙戊酸钠的方法 |
PCT/CN2023/093479 WO2023221851A1 (zh) | 2022-05-16 | 2023-05-11 | 一种联产丙戊酰胺和丙戊酸钠的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210529577.6A CN114763319B (zh) | 2022-05-16 | 2022-05-16 | 一种联产丙戊酰胺和丙戊酸钠的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114763319A CN114763319A (zh) | 2022-07-19 |
CN114763319B true CN114763319B (zh) | 2023-03-31 |
Family
ID=82364941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210529577.6A Active CN114763319B (zh) | 2022-05-16 | 2022-05-16 | 一种联产丙戊酰胺和丙戊酸钠的方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114763319B (zh) |
WO (1) | WO2023221851A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114763319B (zh) * | 2022-05-16 | 2023-03-31 | 湖南大学 | 一种联产丙戊酰胺和丙戊酸钠的方法 |
CN116947600B (zh) * | 2023-07-10 | 2024-04-26 | 湖南省湘中制药有限公司 | 一种丙戊酸工艺杂质2-异丙基戊酸的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2442M (fr) * | 1962-10-17 | 1964-04-06 | Henry Eugene | L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central. |
FR2383907A1 (fr) * | 1977-03-15 | 1978-10-13 | Labaz | Procede de preparation de derives de l'acide acetique et derives obtenus par ce procede |
JPH0662489B2 (ja) * | 1985-10-30 | 1994-08-17 | 日本合成化学工業株式会社 | バルプロ酸の製造法 |
CN103073424B (zh) * | 2013-01-18 | 2014-08-06 | 湖南大学 | 一种丙戊酸衍生物的中间体的绿色制备方法 |
CN103274959B (zh) * | 2013-06-20 | 2015-04-08 | 安徽科技学院 | 一种凉味剂n,2,3-三甲基-2-异丙基丁酰胺的合成方法 |
CN111349003B (zh) * | 2018-12-20 | 2023-10-03 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠的制备方法 |
CN113200844A (zh) * | 2021-03-29 | 2021-08-03 | 上海青平药业有限公司 | 一种丙戊酸钠的制备方法 |
CN113173845A (zh) * | 2021-03-29 | 2021-07-27 | 上海青平药业有限公司 | 一种制备丙戊酸的方法 |
CN114790151B (zh) * | 2022-02-14 | 2023-03-31 | 湖南省湘中制药有限公司 | 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法 |
CN114763328B (zh) * | 2022-02-14 | 2023-03-17 | 湖南大学 | 一种2-氰基-2-丙戊酸的制备方法与应用 |
CN114763319B (zh) * | 2022-05-16 | 2023-03-31 | 湖南大学 | 一种联产丙戊酰胺和丙戊酸钠的方法 |
-
2022
- 2022-05-16 CN CN202210529577.6A patent/CN114763319B/zh active Active
-
2023
- 2023-05-11 WO PCT/CN2023/093479 patent/WO2023221851A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023221851A1 (zh) | 2023-11-23 |
CN114763319A (zh) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114763319B (zh) | 一种联产丙戊酰胺和丙戊酸钠的方法 | |
CN106928227B (zh) | 恩替卡韦的合成方法及其中间体化合物 | |
JP5066447B2 (ja) | 2−ヒドロキシエステル化合物の製造方法 | |
WO2011015287A2 (en) | Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
CN110903163B (zh) | 一种三溴新戊醇的制备方法 | |
CN108623455B (zh) | 一种抗心衰药物的中间体 | |
CN114763328B (zh) | 一种2-氰基-2-丙戊酸的制备方法与应用 | |
CN113087623A (zh) | 一种8-溴辛酸乙酯的合成方法 | |
JP2008162902A (ja) | ジフルオロ酢酸エステルの製造方法 | |
CN114790151B (zh) | 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法 | |
CN109485541B (zh) | 一种制备1h,1h,2h-全氟-1-辛烯的方法 | |
AU2018241503B2 (en) | Process for preparing 2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo(2.2.1)heptane | |
KR19980032744A (ko) | 발프로산의 개선된 제조방법 | |
WO2014077262A1 (ja) | 6,6'-(エチレンジオキシ)ジ-2-ナフトエ酸ジエステルの製造方法 | |
US11384041B2 (en) | Process for preparing an alkoxymethyl alkynyl ether compound having a terminal triple bond | |
CN106674281A (zh) | 一种瑞舒伐他汀中间体化合物、制备方法及其用途 | |
CN115108904A (zh) | 贝派度酸原料药的合成方法 | |
CN116768697B (zh) | 一种氯丙烷作烷化剂制备二丙基丙二酸的方法与应用 | |
CN113149953A (zh) | 一种制备4,5-二甲基-1,3-二氧杂环戊烯-2-酮的方法 | |
KR100906549B1 (ko) | 에틸렌 디티오 카보네이트의 제조방법 | |
CN113735693B (zh) | 一种白藜芦醇三甲醚的合成方法 | |
KR20200069617A (ko) | 플루비프로펜의 제조방법 | |
CN102964311A (zh) | 一种合成4-甲基-5-烷氧基噁唑的方法 | |
CN113121321B (zh) | 一种a-R烷氧基对氯苄基磷酸单酯的回收及其再利用方法 | |
CN106866739B (zh) | 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230602 Address after: 422002 No. 18, Daxing South Road, Baoqing industrial concentration zone, Shaoyang City, Hunan Province Patentee after: Hunan Province Xiangzhong Pharmaceutical Co.,Ltd. Patentee after: HUNAN University Address before: Yuelu District City, Hunan province 410082 Changsha Lushan Road No. 1 Hunan University Patentee before: HUNAN University |